Allergan Plc (AGN) 268.55 $AGN
Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:15AM CDT
Acorda Therapeutics' (ACOR) third-quarter 2015 earnings came in at 11 cents per share, while the Zacks Consensus Estimate was pegged at a loss of 12 cents.
AGN: 268.55 (+15.51), BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44), ACOR: 36.14 (+1.22)
Allergan Down 11.9% Since SmarTrend Downtrend Call (AGN)
Comtex SmarTrend(R) - Fri Oct 23, 9:59AM CDT
SmarTrend identified a Downtrend for Allergan (NYSE:AGN) on August 21st, 2015 at $298.94. In approximately 2 months, Allergan has returned 11.88% as of today's recent price of $263.42.
AGN: 268.55 (+15.51)
Global Exocrine Pancreatic Insufficiency Pipeline Review, H2 2015 - 5 Companies & 5 Drug Profiles
M2 - Fri Oct 23, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mjv77n/exocrine) has announced the addition of the "Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Anthera Pharmaceuticals Inc. - Cilian AG - Laboratoires Mayoly Spindler S.A.S. - Nordmark Arzneimittel GmbH & Co. KG Drug Profiles - burlulipase - Cilase - liprotamase - MS-1819 - pancrelipase DR For more information visit http://www.researchandmarkets.com/research/mjv77n/exocrine
AGN: 268.55 (+15.51), ANTH: 5.85 (-0.02)
Global Female Contraceptives Market 2015-2019 with Allergan, Merck, Pfizer & Teva Pharmaceutical Dominating
PR Newswire Europe - Fri Oct 23, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3phl9t/global_female [http://www.researchandmarkets.com/research/3phl9t/global_female]) has announced the addition of the "Global Female Contraceptives Market 2015-2019" [http://www.researchandmarkets.com/research/3phl9t/global_female] report to their offering.
AGN: 268.55 (+15.51), MRK: 52.88 (+0.87)
Research and Markets: Global Female Contraceptives Market 2015-2019 with Allergan, Merck, Pfizer & Teva Pharmaceutical Dominating
Business Wire - Fri Oct 23, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8qn8j/global_female) has announced the addition of the "Global Female Contraceptives Market 2015-2019" report to their offering.
AGN: 268.55 (+15.51), MRK: 52.88 (+0.87)
How Short Sellers Run this Market: Part 1
at The Street - Thu Oct 22, 10:43AM CDT
First, the sectors where shorts are making big money.
KMI: 29.23 (-0.52), AGN: 268.55 (+15.51), HCA: 68.98 (+2.90), VRX: 116.16 (+6.29), SWKS: 82.55 (+0.86), CYH: 28.71 (+2.41), NXPI: 96.09 (-1.86), AVGO: 129.58 (+4.24), HRZN: 9.95 (+0.07)
RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off
at The Street - Thu Oct 22, 9:46AM CDT
The selloff in specialty pharmaceutical stocks has found a new "irrational low," following Wednesday's attack on Valeant Pharmaceuticals, according to RBC Capital Markets.
AGN: 268.55 (+15.51), ENDP: 56.60 (+5.14), INSY: 22.65 (+0.69), VRX: 116.16 (+6.29), SGNT: 16.38 (+1.11), IBB: 316.28 (+10.17), TEVA: 59.55 (+3.59)
Trigeminal Neuralgia Pipeline Review, H2 2015 - 4 Companies & 5 Drug Profiles
M2 - Thu Oct 22, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t353hr/trigeminal) has announced the addition of the "Trigeminal Neuralgia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Trigeminal Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trigeminal Neuralgia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Convergence Pharmaceuticals Ltd. - Merz Pharma GmbH & Co. KgaA - Trigemina, Inc. Drug Profiles - (naltrexone hydrochloride clonidine hydrochloride) - incobotulinumtoxin A - onabotulinumtoxin A - oxytocin - raxatrigine hydrochloride For more information visit http://www.researchandmarkets.com/research/t353hr/trigeminal
AGN: 268.55 (+15.51)
Valeant Dives As Short Seller Alleges Pharmacy Fraud
at Investor's Business Daily - Wed Oct 21, 4:02PM CDT
Embattled drugmaker Valeant Pharmaceuticals (VRX) tumbled nearly 40% Wednesday to a two-year low and closed down 19.2%, as short-selling outfit Citron Research charged it with a complex fraud involving multiple specialty pharmacies. Valeant responded...
AGN: 268.55 (+15.51), ENDP: 56.60 (+5.14), VRX: 116.16 (+6.29)
Ocular (OCUL) Initiates Third Phase III Study on Dextenza
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:25PM CDT
Ocular (OCUL) initiated patient enrolment in the third phase III study on Dextenza for the treatment of post-surgical ocular inflammation and pain.
AGN: 268.55 (+15.51), OCUL: 7.18 (-7.88), NVS: 92.98 (+0.55)
Allergan Issues Statement On Specialty Pharmacy Utilization
PR Newswire - Wed Oct 21, 11:07AM CDT
Allergan plc (NYSE: AGN), today issued the following statement regarding specialty pharmacy utilization.
AGN: 268.55 (+15.51)
Next Support Level for Allergan (AGN) is $248.35
Comtex SmarTrend(R) - Wed Oct 21, 9:05AM CDT
Allergan (NYSE:AGN) has opened bearishly below the pivot of $265.04 today and has reached the first level of support at $255.88. Investors may be interested in a cross of the next downside pivot targets of $248.35 and $231.66.
AGN: 268.55 (+15.51)
Allergan Expands Dry Eye Portfolio With Launch Of REFRESH OPTIVE® Gel Drops
PR Newswire - Wed Oct 21, 7:01AM CDT
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the launch of the over-the-counter artificial tear REFRESH OPTIVE® Gel Drops, a new aqueous gel expertly designed for patients who need or desire a more viscous artificial tear option to relieve their Dry Eye symptoms. From REFRESH®, the creators of the number one doctor recommended brand of artificial tears1, new REFRESH OPTIVE® Gel Drops are formulated with Glycerin and a unique blend of the active ingredient CMC which binds to the eye surface to provide long-lasting relief from Dry Eye discomfort.
AGN: 268.55 (+15.51)
SmarTrend Watching for Potential Rebound in Shares of Allergan After 3.62% Loss
Comtex SmarTrend(R) - Tue Oct 20, 3:45PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $257.50 to a high of $274.19. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $261.17 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 268.55 (+15.51)
Cempra Antibiotic Meets Endpoints, Adverse Events Concerning
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:35PM CDT
Cempra, Inc. (CEMP) announced positive top-line results from a global, phase III study on pipeline candidate intravenous to oral solithromycin.
AGN: 268.55 (+15.51), PFE: 34.05 (+0.72), CEMP: 18.00 (+2.24)
Supernus Inks Trokendi XR Settlement Agreement with Endo
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:25PM CDT
Supernus (SUPN) inked a settlement agreement with Par Pharmaceutical (Endo's wholly owned subsidiary) for an ongoing patent litigation regarding Trokendi XR.
AGN: 268.55 (+15.51), ENDP: 56.60 (+5.14), ADHD: 6.73 (+0.45), SUPN: 15.97 (+0.70)
Rotation Is Enough to Make Your Head Spin
at The Street - Tue Oct 20, 1:17PM CDT
Bad news isn't always a bad thing.
AMZN: 599.03 (+35.12), TSLA: 209.09 (-2.63), VRX: 116.16 (+6.29), HOG: 48.20 (+0.09), LMT: 219.32 (+2.81), ETN: 54.31 (-0.04), CLX: 123.25 (-0.35), UTX: 100.62 (+0.83), DAL: 51.00 (+0.19), CELG: 120.08 (+2.82), AGN: 268.55 (+15.51), GILD: 107.99 (+0.39), IBM: 144.68 (+0.59), GOOGL: 719.33 (+38.19), DOV: 64.44 (+0.44), PG: 77.03 (+2.18), PPG: 103.99 (+0.37), REGN: 536.70 (+11.59)
Global Physician Dispensed Cosmeceutical Industry - Reportlinker Review
PR Newswire - Tue Oct 20, 11:58AM CDT
This report analyzes the worldwide markets for Physician Dispensed Cosmeceuticals in US$ Thousand by the following Segments: Physician Dispensed Skin Care Products, and Physician Dispensed Eyelash Products. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 74 companies including many key and niche players such as -
AGN: 268.55 (+15.51)
Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:15AM CDT
Acorda Therapeutics' (ACOR) third-quarter 2015 earnings came in at 11 cents per share, while the Zacks Consensus Estimate was pegged at a loss of 12 cents.
AGN: 268.55 (+15.51), BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44), ACOR: 36.14 (+1.22)
Allergan Down 11.9% Since SmarTrend Downtrend Call (AGN)
Comtex SmarTrend(R) - Fri Oct 23, 9:59AM CDT
SmarTrend identified a Downtrend for Allergan (NYSE:AGN) on August 21st, 2015 at $298.94. In approximately 2 months, Allergan has returned 11.88% as of today's recent price of $263.42.
AGN: 268.55 (+15.51)
Global Exocrine Pancreatic Insufficiency Pipeline Review, H2 2015 - 5 Companies & 5 Drug Profiles
M2 - Fri Oct 23, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mjv77n/exocrine) has announced the addition of the "Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Exocrine Pancreatic Insufficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Exocrine Pancreatic Insufficiency and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Anthera Pharmaceuticals Inc. - Cilian AG - Laboratoires Mayoly Spindler S.A.S. - Nordmark Arzneimittel GmbH & Co. KG Drug Profiles - burlulipase - Cilase - liprotamase - MS-1819 - pancrelipase DR For more information visit http://www.researchandmarkets.com/research/mjv77n/exocrine
AGN: 268.55 (+15.51), ANTH: 5.85 (-0.02)
Global Female Contraceptives Market 2015-2019 with Allergan, Merck, Pfizer & Teva Pharmaceutical Dominating
PR Newswire Europe - Fri Oct 23, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3phl9t/global_female [http://www.researchandmarkets.com/research/3phl9t/global_female]) has announced the addition of the "Global Female Contraceptives Market 2015-2019" [http://www.researchandmarkets.com/research/3phl9t/global_female] report to their offering.
AGN: 268.55 (+15.51), MRK: 52.88 (+0.87)
Research and Markets: Global Female Contraceptives Market 2015-2019 with Allergan, Merck, Pfizer & Teva Pharmaceutical Dominating
Business Wire - Fri Oct 23, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v8qn8j/global_female) has announced the addition of the "Global Female Contraceptives Market 2015-2019" report to their offering.
AGN: 268.55 (+15.51), MRK: 52.88 (+0.87)
How Short Sellers Run this Market: Part 1
at The Street - Thu Oct 22, 10:43AM CDT
First, the sectors where shorts are making big money.
KMI: 29.23 (-0.52), AGN: 268.55 (+15.51), HCA: 68.98 (+2.90), VRX: 116.16 (+6.29), SWKS: 82.55 (+0.86), CYH: 28.71 (+2.41), NXPI: 96.09 (-1.86), AVGO: 129.58 (+4.24), HRZN: 9.95 (+0.07)
RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off
at The Street - Thu Oct 22, 9:46AM CDT
The selloff in specialty pharmaceutical stocks has found a new "irrational low," following Wednesday's attack on Valeant Pharmaceuticals, according to RBC Capital Markets.
AGN: 268.55 (+15.51), ENDP: 56.60 (+5.14), INSY: 22.65 (+0.69), VRX: 116.16 (+6.29), SGNT: 16.38 (+1.11), IBB: 316.28 (+10.17), TEVA: 59.55 (+3.59)
Trigeminal Neuralgia Pipeline Review, H2 2015 - 4 Companies & 5 Drug Profiles
M2 - Thu Oct 22, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t353hr/trigeminal) has announced the addition of the "Trigeminal Neuralgia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Trigeminal Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Trigeminal Neuralgia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Allergan Plc - Convergence Pharmaceuticals Ltd. - Merz Pharma GmbH & Co. KgaA - Trigemina, Inc. Drug Profiles - (naltrexone hydrochloride clonidine hydrochloride) - incobotulinumtoxin A - onabotulinumtoxin A - oxytocin - raxatrigine hydrochloride For more information visit http://www.researchandmarkets.com/research/t353hr/trigeminal
AGN: 268.55 (+15.51)
Valeant Dives As Short Seller Alleges Pharmacy Fraud
at Investor's Business Daily - Wed Oct 21, 4:02PM CDT
Embattled drugmaker Valeant Pharmaceuticals (VRX) tumbled nearly 40% Wednesday to a two-year low and closed down 19.2%, as short-selling outfit Citron Research charged it with a complex fraud involving multiple specialty pharmacies. Valeant responded...
AGN: 268.55 (+15.51), ENDP: 56.60 (+5.14), VRX: 116.16 (+6.29)
Ocular (OCUL) Initiates Third Phase III Study on Dextenza
Zacks Equity Research - Zacks Investment Research - Wed Oct 21, 3:25PM CDT
Ocular (OCUL) initiated patient enrolment in the third phase III study on Dextenza for the treatment of post-surgical ocular inflammation and pain.
AGN: 268.55 (+15.51), OCUL: 7.18 (-7.88), NVS: 92.98 (+0.55)
Allergan Issues Statement On Specialty Pharmacy Utilization
PR Newswire - Wed Oct 21, 11:07AM CDT
Allergan plc (NYSE: AGN), today issued the following statement regarding specialty pharmacy utilization.
AGN: 268.55 (+15.51)
Next Support Level for Allergan (AGN) is $248.35
Comtex SmarTrend(R) - Wed Oct 21, 9:05AM CDT
Allergan (NYSE:AGN) has opened bearishly below the pivot of $265.04 today and has reached the first level of support at $255.88. Investors may be interested in a cross of the next downside pivot targets of $248.35 and $231.66.
AGN: 268.55 (+15.51)
Allergan Expands Dry Eye Portfolio With Launch Of REFRESH OPTIVE® Gel Drops
PR Newswire - Wed Oct 21, 7:01AM CDT
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the launch of the over-the-counter artificial tear REFRESH OPTIVE® Gel Drops, a new aqueous gel expertly designed for patients who need or desire a more viscous artificial tear option to relieve their Dry Eye symptoms. From REFRESH®, the creators of the number one doctor recommended brand of artificial tears1, new REFRESH OPTIVE® Gel Drops are formulated with Glycerin and a unique blend of the active ingredient CMC which binds to the eye surface to provide long-lasting relief from Dry Eye discomfort.
AGN: 268.55 (+15.51)
SmarTrend Watching for Potential Rebound in Shares of Allergan After 3.62% Loss
Comtex SmarTrend(R) - Tue Oct 20, 3:45PM CDT
Allergan (NYSE:AGN) traded in a range yesterday that spanned from a low of $257.50 to a high of $274.19. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $261.17 on volume of 4.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 268.55 (+15.51)
Cempra Antibiotic Meets Endpoints, Adverse Events Concerning
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:35PM CDT
Cempra, Inc. (CEMP) announced positive top-line results from a global, phase III study on pipeline candidate intravenous to oral solithromycin.
AGN: 268.55 (+15.51), PFE: 34.05 (+0.72), CEMP: 18.00 (+2.24)
Supernus Inks Trokendi XR Settlement Agreement with Endo
Zacks Equity Research - Zacks Investment Research - Tue Oct 20, 3:25PM CDT
Supernus (SUPN) inked a settlement agreement with Par Pharmaceutical (Endo's wholly owned subsidiary) for an ongoing patent litigation regarding Trokendi XR.
AGN: 268.55 (+15.51), ENDP: 56.60 (+5.14), ADHD: 6.73 (+0.45), SUPN: 15.97 (+0.70)
Rotation Is Enough to Make Your Head Spin
at The Street - Tue Oct 20, 1:17PM CDT
Bad news isn't always a bad thing.
AMZN: 599.03 (+35.12), TSLA: 209.09 (-2.63), VRX: 116.16 (+6.29), HOG: 48.20 (+0.09), LMT: 219.32 (+2.81), ETN: 54.31 (-0.04), CLX: 123.25 (-0.35), UTX: 100.62 (+0.83), DAL: 51.00 (+0.19), CELG: 120.08 (+2.82), AGN: 268.55 (+15.51), GILD: 107.99 (+0.39), IBM: 144.68 (+0.59), GOOGL: 719.33 (+38.19), DOV: 64.44 (+0.44), PG: 77.03 (+2.18), PPG: 103.99 (+0.37), REGN: 536.70 (+11.59)
Global Physician Dispensed Cosmeceutical Industry - Reportlinker Review
PR Newswire - Tue Oct 20, 11:58AM CDT
This report analyzes the worldwide markets for Physician Dispensed Cosmeceuticals in US$ Thousand by the following Segments: Physician Dispensed Skin Care Products, and Physician Dispensed Eyelash Products. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 74 companies including many key and niche players such as -
AGN: 268.55 (+15.51)
